Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2024 07:50 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
October 15, 2024 07:50 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
July 25, 2024 07:57 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
January 31, 2024 07:57 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).